暗网禁区

Education

• 2000 – 2003: Completed Hematology training at the Department of Hematology, University of Ferrara Medical School, Ferrara, Italy; obtained degree with honours
• 1999: Obtained Medical Degree with honours, University of Pavia Medical School, Pavia, Italy

Academic Appointments

• 2015 – 2016: Associate Professor of Hematology, 暗网禁区 University, and Head of the Leukemia Unit, Cancer Center, 暗网禁区 Research Hospital
• 2015 – 2008: Associate Professor of Clinical Oncology, University of Pavia Medical School & S. Matteo Hospital

Awards and Honors

• 2004 – 2006: Awarded a postdoctoral fellowship at the Department of Hematology, University of Pavia Medical School & S. Matteo Hospital, Pavia, Italy. Research project: 鈥淕enomic and functional characterization of hematopoietic stem cells in myelodysplastic syndromes.鈥�

Current research interests mainly concern acute leukemia, myelodysplastic syndromes and myeloproliferative neoplasms (myeloid malignancies)

These investigations led to the definition of specific gene expression profiles in myelodysplastic syndromes [Blood. 2006;108(1):337-45, Leukemia. 2010;24(4):756-64 and J Clin Oncol 2013;31(28):3557-64: J Clin Oncol. 2016;34(30):3627-3637], to the identification of the molecular basis of refractory anemia with ringed sideroblasts associated with marked thrombocytosis [Blood. 2009;114(17):3538-45], and to the development of the WPSS [J Clin Oncol. 2007;25(23):3503-10 and Blood. 2008;112(3):895-902; Leukemia. 2017;31(11):2449-2457] and the CPSS [Blood. 2013;121(15):3005-15] as a valuable tools for risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative disorders, respectively.

• In 2008 he joined the European LeukemiaNet working package on myelodysplastic syndromes, aimed at developing European evidence and consensus-based guidelines for the diagnosis and treatment of myelodysplastic syndromes [Blood. 2013 Oct 24;122(17):2943-64]
• In 2010, he joined the International Cancer Genome Consortium Chronic Myeloid Disorders Working Group. This collaboration led to the identification of somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts [N Engl J Med. 2011; 365(15):1384-95, Blood. 2011;118(24):6239-46, Blood. 2015 Jul 9;126(2):233-41, Leukemia. 2015 Jan;29(1):66-75].